Apr 25, 2025
The 77th Annual Meeting of the American Academy of Neurology (AAN 2025), held from April 5–9 in San Diego and online, served as a pivotal forum for advancing research in neurology, with particular relevance to neurodegenerative diseases. As one of the largest gatherings of neurologists globally, the conference prov...
Read More...
Apr 18, 2025
The Alzheimer's and Parkinson's Diseases (AD/PD) 2025 International Conference, conducted in April in Vienna, Austria, and online, stands as a pivotal event in neurodegenerative disease research. This hybrid gathering brings together global experts to delve into the latest advancements in Alzheimer’s and Parkinson’...
Read More...
Mar 27, 2019
Alzheimer’s is one of the diseases which are irreversible and untreatable. With causes still unknown adds to the further conundrum. But for more than two decades now Scientists from everywhere have been working on the “amyloid hypothesis". It has been a long-standing theory that brains of the people affected ...
Read More...
Feb 16, 2018
Vertex pharmaceutical’s growth story in biotech with Symdeko’s approval FDA has recently approved Vertex Pharmaceutical’s latest combination treatment, Symdeko, to serve the cystic fibrosis patient population. Symdeko's annual list price has been set at USD 292,000. Symdeko has paired with a fresh corrector, tezacaf...
Read More...
Sep 28, 2017
Another flop for Alzeimer’s as Late Stage drug of AxovantSciences fails in trial Axovant Sciences has reported the failure of their late-stage trial involving the testing of its pill Intepirdinecould not suppress Alzheimer's symptoms in participants of the trail. The news had plunged the Wall Street into another wav...
Read More...
LEQEMBI: A New Hope for Alzheimer’s Disease Patients
Feb 12, 2025
Roche’s HER2-Positive Breast Cancer Treatment Franchise
Aug 13, 2024
Newsletter/Whitepaper